supreme court Stories
- Coca-Cola's Minute Maid brand has been advertising a product as pomegranate blueberry juice. In fact, only 0.5 percent of it is.
- Sotomayor must decide whether a religious non-profit will be allowed to exercise its religious rights on its terms or make it abide by exceptions to the contraception coverage under the Affordable Care Act.
- The U.S. Supreme Court refused to hear an appeal from Ex-InterMune CEO W. Scott Harkonen after he was convicted of fraud for misrepresenting the use of the company's drug Actimmune.
- The U.S. Supreme Court agreed to review whether the Affordable Care Act's birth control mandate violates employers' freedom of religion.
- The U.S. Supreme Court has denied an emergency application to vacate the ruling of the appellate court that allowed the restrictive Texas abortion law to take effect.
- Rights groups opposing the new Texas abortion law have asked the US Supreme Court to block some of its provisions.
- Officials in one Pennsylvania school district say that 'I Heart Boobies' bracelets for breast cancer awareness are so lewd and disruptive that they warrant suspension.
- The Nebraska Supreme Court upheld a lower court's decision to reject a 16-year-old girl's request to have an abortion, drawing criticism from news outlets and dissenting judges.
- Generic drug companies cannot be sued by patients who have adverse reactions because these companies did not design the drugs nor pursue the initial FDA approval process, says the Supreme Court.
Myriad Genetics Helped By Supreme Court Ruling Against Gene Patents; Is The Cure For Cancer On Its Way?The Supreme Court decision does away with patents and monopolies over lifesaving scientific information that may lead to the cure for cancer.
Supreme Court Gene Patent Case: Unanimous Decision Allows Companies To Patent Synthetic Gene Material, But Not Human GenesIn a historic gene patent case, the Supreme Court unanimously ruled in Thursday that human genes cannot be patented.
- The Supreme Court agreed on Friday to decide whether brand-name drug companies may pay money to generic drug rivals to keep their lower-priced products off the market.